The FDA has approved a new pediatric dosage form and label changes for atazanavir. Please see the FDA announcement for more information.
Type your search term(s) in the text box. Users can only search one guideline at a time. To search for an exact phrase, use quotation marks (i.e. "what to start"). To narrow your search, add additional relevant terms. If you are not finding what you need, try searching similar terms (i.e. perinatal OR pregnancy) to broaden your search.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
Entry and Fusion Inhibitors
(Last updated: February 12, 2014; last reviewed: February 12, 2014)
When given with potent CYP3A inhibitors (with or without CYP3A inducers) including protease inhibitors (except ritonavir-boosted tipranavir)
150 mg twice daily
When given with nucleoside reverse transcriptase inhibitors, enfuvirtide, ritonavir-boosted tipranavir, nevirapine, raltegravir, and drugs that are not potent CYP3A inhibitors or inducers
300 mg twice daily
When given with potent CYP3A inducers including efavirenz and etravirine (without a potent CYP3A inhibitor)
600 mg twice daily
Selected Adverse Events
Upper respiratory tract infections
Hepatotoxicity (which may be preceded by severe rash and/or other signs of systemic allergic reaction)
Orthostatic hypotension (especially in patients with severe renal insufficiency)
Conduct testing with HIV tropism assay (see Antiretroviral Drug-Resistance Testing in the main body of the guidelines) before using MVC to exclude the presence of CXCR4-using or mixed/dual-tropic HIV. Use maraviroc in patients with only CCR5-tropic virus. Do not use if CXCR4 or mixed/dual-tropic HIV is present.
Maraviroc can be given without regard to food.
Instruct patients on how to recognize symptoms of allergic reactions or hepatitis.
Use caution when administering maraviroc to patients with underlying cardiac disease.
Cytochrome P450 3A4 (CYP3A4) substrate
Dosing of maraviroc in patients with hepatic impairment: Use caution when administering maraviroc to patients with hepatic impairment. Because maraviroc is metabolized by the liver, concentrations in patients with hepatic impairment may be increased.
Do not use maraviroc in patients with creatinine clearance <30 mL/min who are receiving potent CYP3A4 inhibitors or inducers.
Dosing of maraviroc in patients with renal impairment: Refer to the manufacturer’s prescribing information.
Absorption: Absorption of maraviroc is somewhat reduced with ingestion of a high-fat meal; however, maraviroc can be given with or without food.
Metabolism: Maraviroc is a CYP3A4 and p-glycoprotein (Pgp) substrate and requires dosage adjustments when administered with CYP- or Pgp-modulating medications.
Before administration, a patient’s medication profile should be carefully reviewed for potential drug interactions with maraviroc.
More common: Cough, fever, upper respiratory tract infections, rash, musculoskeletal symptoms, abdominal pain, and dizziness.
Less common (more severe): Hepatotoxicity that may be preceded by evidence of a systemic allergic reaction (such as pruritic rash, eosinophilia or elevated immunoglobulin) has been reported. Serious adverse events occurred in less than 2% of maraviroc-treated adult patients and included cardiovascular abnormalities (e.g., angina, heart failure, myocardial infarction), hepatic cirrhosis or failure, cholestatic jaundice, viral meningitis, pneumonia, myositis, osteonecrosis, and rhabdomyolysis.
The pharmacokinetics (PK), safety, and efficacy of maraviroc in patients aged <16 years have not been established. A dose-finding and efficacy study is under way in children aged 2 to 17 years.1,2 In this trial, maraviroc dose is based upon body surface area and the presence or absence of a potent CYP3A4 inhibitor in the background regimen. Preliminary PK data are encouraging in those on a potent CYP3A4 inhibitor, but low exposures were seen in those not on a potent CYP3A4 inhibitor. Enrollment of and follow up with participants in this trial continues.
Vourvahis M. Update from Study A4001031: maraviroc pharmacokinetics in CCR5-tropic HIV-1-infected children aged 2 to < 18 years. Paper presented at: The 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2013; Kuala Lumpur, Malaysia.
Giaquinto C. Safety and efficacy of maraviroc in CCR5-tropic HIV-1-infected children aged 2 to < 18 years. Paper presented at: 7th IAS Conference on HIV Pathogenesis Treatment and Prevention; June 30-July 3, 2013, 2013; Kuala Lumpur, Malaysia.